Etelcalcetide
Etelcalcetide is an FDA-approved calcium-sensing receptor agonist. Etelcalcetide is a synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells at a site distinct from the calcium binding site, forming a disulfide bond with a cysteine residue on the receptor.
For research use only.
Key Facts
- CAS
- 1262780-97-1
- Molecular Weight (MW)
- 1048.3 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- intravenous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Peptide calcimimetic approved for secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis. It is given intravenously at the end of dialysis rather than orally.
Peptide Library's Etelcalcetide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- intravenous
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Etelcalcetide is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C38H73N21O10S2 |
|---|---|
| Molecular weight | 1048.3 g/mol |
| CAS number | 1262780-97-1 |
| PubChem CID | 71511839 |
| FDA UNII | 60ME133FJB |
| ChEMBL | CHEMBL3545184 |
| DrugBank | DB12865 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Etelcalcetide is a synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells at a site distinct from the calcium binding site, forming a disulfide bond with a cysteine residue on the receptor. This allosteric activation increases receptor sensitivity to extracellular calcium, suppressing parathyroid hormone secretion and lowering serum calcium and phosphate.
Studies
- Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial
- Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis
- Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies
- Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients
- Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease
Regulatory & research status
Etelcalcetide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Etelcalcetide: frequently asked questions
What is Etelcalcetide?
Peptide calcimimetic approved for secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis. It is given intravenously at the end of dialysis rather than orally.
How does Etelcalcetide work?
Etelcalcetide is a synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells at a site distinct from the calcium binding site, forming a disulfide bond with a cysteine residue on the receptor. This allosteric activation increases receptor sensitivity to extracellular calcium, suppressing parathyroid hormone secretion and lowering serum calcium and phosphate.
Is Etelcalcetide FDA approved?
Yes. Etelcalcetide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Etelcalcetide?
Compounds most often compared with Etelcalcetide include Angiotensin II, Cetrorelix, Corticorelin and Cosyntropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial — JAMA, 2017External reference
- Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis — Eur J Clin Pharmacol, 2024External reference
- Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies — Ther Apher Dial, 2024External reference
- Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients — Curr Osteoporos Rep, 2023External reference
- Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease — Curr Opin Nephrol Hypertens, 2022External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Etelcalcetide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Etelcalcetide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →